• Neethu R
• Vedika Babasaheb Dagadkhair
• Amruta Gaikwad
• Shraddha Pachare
• Sakshi Tembare,Tanishka Tandel

Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease (1).In India, more than 4 million people have some form of dementia. Worldwide, at least 44 million people are living with dementia, making the disease a global health crisis that must be addressed(2).It is the fourth leading cause of death in the United States and is becoming prevalent in many other countries. The total brain size shrinks with Alzheimer’s - the issue has progressively fewer nerve cells and connections. As such there is no known cure for Alzheimer’s disease the death of brain cells in dementia cannot be halted or reversed. Along with an aim to improve research into prevention and treatment, the goals of the plan also include measures for present interventions. To help people suffering expand support for people with Alzheimer’s disease and their families, enhance public awareness and engagement and expand your support towards them. Enhance care quality and efficiency. There are no disease-modifying drugs available for Alzheimer’s disease but some options may reduce its symptoms and help improve quality of life and thereby help the patients to some extent. There are four drugs in a class called cholinesterase inhibitors approved for symptomatic relief i.e.Donepezil (brand name Aricept), Alantamine (Reminyl), Rivastigmine, and Tacrine (Cognex). A different kind of drug, memantine (Namenda), an N-methyl-D-aspartate (NMDA) receptor antagonist, may also be used, alone or in combination with a cholinesterase inhibitor. As with other types of dementia and neurodegenerative disease, a major part of therapy for patients with Alzheimer’s comes from the support given by healthcare workers to provide dementia quality-of-life care, which becomes more important as needs increase with declining independence and increasing dependence(3).

Amyloid Plaque, Cholinesterase, NMDA Antagonist, Immunotherapy.

"Alzheimer's Disease: Modern Treatment & Strategy - A Review", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 6, page no.f264-f269, June-2024, Available :http://www.jetir.org/papers/JETIR2406529.pdf

"Alzheimer's Disease: Modern Treatment & Strategy - A Review", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 6, page no. ppf264-f269, June-2024, Available at : http://www.jetir.org/papers/JETIR2406529.pdf